221040-07-9

Basic information

• Product Name: 4-BENZYLOXY-2-FLUORO-1-NITROBENZENE
• Synonyms: 4-BENZYLOXY-2-FLUORO-1-NITROBENZENE;4-Benzyloxy-2-fluoro-1-nitrobenzene 98%;4-Benzyloxy-2-fluoro-1-nitrobenzene98%
• CAS NO: 221040-07-9
• Molecular Formula: C₁₃H₁₀FNO₃
• Molecular Weight: 247.2218032
• Product Categories: blocks;FluoroCompounds;NitroCompounds
• Mol File: 221040-07-9.mol

Chemical Properties

• Boiling Point: 385.3°Cat760mmHg
• Flash Point: 186.8°C
• Appearance: /
• Density: 1.299g/cm³
• CAS DataBase Reference: 4-BENZYLOXY-2-FLUORO-1-NITROBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BENZYLOXY-2-FLUORO-1-NITROBENZENE(221040-07-9)
• EPA Substance Registry System: 4-BENZYLOXY-2-FLUORO-1-NITROBENZENE(221040-07-9)

Safety Data

• Hazard Codes: Xi,C
• Statements: 34
• Safety Statements: 36/37-45
• Hazardous Substances Data: 221040-07-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-BENZYLOXY-2-FLUORO-1-NITROBENZENE is used as a key intermediate in organic synthesis for its ability to contribute to the formation of a variety of complex organic molecules. Its unique structure allows for versatile chemical reactions, making it a preferred component in the synthesis of advanced organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-BENZYLOXY-2-FLUORO-1-NITROBENZENE is utilized as a building block for the development of new drugs. Its structural features make it a promising candidate for the creation of pharmaceuticals with potential therapeutic applications.
Used in the Production of Pharmaceuticals and Agrochemicals:
4-BENZYLOXY-2-FLUORO-1-NITROBENZENE is employed as an intermediate in the manufacturing process of various pharmaceuticals and agrochemicals. Its presence in these products is crucial for their efficacy and performance.
Used in Medicinal Chemistry Research:
4-BENZYLOXY-2-FLUORO-1-NITROBENZENE is also considered an important tool in medicinal chemistry research. It has been studied for its potential biological activities, which could lead to the discovery of new therapeutic agents and contribute to the advancement of medical science.

Upstream product

• 446-35-5 2,4-Difluoronitrobenzene 
• 100-39-0 benzyl bromide 
• 100-51-6 benzyl alcohol 
• 394-41-2 3-fluoro-4-nitrophenol 
• 311-28-4 tetra-(n-butyl)ammonium iodide 

Downstream Products

• 221040-10-4 N-(5-benzyloxy-2-nitrophenyl)-1,2,3,4-tetrahydroisoquinoline 
• 221040-11-5 N-(5-benzyloxy-2-nitrophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 1329118-28-6 2-(2-chloro-6-fluorophenyl)-1H-imidazole-4-carboxylic acid (6-benzyloxy-1-cyclopentyl-1H-benzimidazol-2-yl)amide 
• 1329119-55-2 4-benzyloxy-N₂-cyclopentyl-benzene-1,2-diamine 
• 1329119-56-3 6-benzyloxy-1-cyclopentyl-1H-benzimidazol-2-ylamine 
• 1329119-54-1 (5-benzyloxy-2-nitro-phenyl)-cyclopentyl-amine 
• 1266247-03-3 5-benzyloxy-N-ethyl-2-nitroaniline 
• 496838-02-9 N-(6-benzyloxy-1-methyl-1H-benzoimidazol-2-yl)-benzamide 
• 496837-95-7 5-(benzyloxy)-N₁-methylbenzene-1,2-diamine 
• 496837-94-6 5-(benzyloxy)-N-methyl-2-nitroaniline 
• 1232234-07-9 4-(3-chloro-phenyl)-2-{6-[4-(4-methyl-piperazin-1-yl)-butoxy]-benzoimidazol-1-yl}-thiazole-5-carboxylic acid amide 
• 1232234-05-7 2-(6-{3-[bis-(2-hydroxy-ethyl)-amino]-propoxy}-benzoimidazol-1-yl)-4-(3-chloro-phenyl)-thiazole-5-carboxylic acid amide 
• 1232234-09-1 4-(3-chloro-phenyl)-2-{6-[2-hydroxy-3-(4-methyl-piperazin-1-yl)-propoxy]-benzoimidazol-1-yl}-thiazole-5-carboxylic acid amide 

Relevant articles and documents

COMPOUNDS FOR USE IN THE TREATMENT OF FASCIOLIASIS

The present invention relates to compounds of formula (1a), (1b), (1c), (1d) or (1e) and pharmaceutically acceptable salts or solvates thereof for use in the treatment or prevention of fascioliasis. Some of these compounds are novel per se and also have activity as inhibitors of Schistosoma growth. The invention also relates to pharmaceutical compositions comprising such novel compounds, salts or solvates and to the use of such novel compounds as medicaments, in particular in the treatment or prevention of schistosomiasis, also known as bilharzia.

NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

Compound of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, X, Y and G are as defined in the description, and their use in the manufacture of medicaments.

PHENYLACETAMIDES AS INHIBITORS OF ROCK

The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

COMPOUNDS AND THEIR USE IN THE TREATMENT OF SCHISTOSOMIASIS

The present invention relates to novel compounds and pharmaceutically acceptable salts or solvates thereof which have activity as inhibitors of Schistosoma growth. The invention also relates to pharmaceutical compositions comprising such compounds, salts or solvates and to the use of such compounds as medicaments, in particular in the treatment or prevention of schistosomiasis, also known as bilharzia.

NOVEL MEDICINE COMPOSED OF BENZIMIDAZOLE COMPOUND

PROBLEM TO BE SOLVED: To provide an agent for treating or preventing a disease associated with SCN9A(Nav1.7). SOLUTION: The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. [R1a, R1b, R1c, R1d: H, halogen, cyano, C1-4 alkyl, C1-4 alkoxy or the like. R2, R3: H, C1-6 alkyl, C3-10 cycloalkyl or the like. R4: H, C1-6 alkyl, C3-7 cycloalkyl or the like. m: 1, 2 or 3. L: CR7R8(R7, R8: H, OH, C1-4 alkyl, C1-4 alkoxy or the like)]. SELECTED DRAWING: None COPYRIGHT: (C)2019,JPOandINPIT

NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF

The present invention provides a medicament for treating a disease involving Nav 1.7 such as neuropathic pain, nociceptive pain, inflammatory pain, small-fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria, and multiple sclerosis, which comprises a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c and R1d are hydrogen, halogen, cyano, C1-4 alkyl, C1-4 alkoxy, or the like, provided that at least one of R1a, R1b, R1c and R1d is C6-10 aryl, C6-10 aryloxy, or the like, R2 and R3 are hydrogen, C1-6 alkyl, C3-10 cycloalkyl, or the like, R4 is hydrogen, C1-6 alkyl, C3-7 cycloalkyl, or the like, m is 1, 2 or 3, L is CR7R8, and R7 and R8 are hydrogen, hydroxyl, C1-4 alkyl, C1-4 alkoxy, or the like.

NOVEL TETRA- AND PENTASUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS

The present invention relates to compounds of general formula (I) and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.

Nonpolar solvent a key for highly regioselective SNAr reaction in the case of 2,4-difluoronitrobenzene

A practical and highly regioselective aromatic nucleophilic substitution reaction for the substrate 2,4-difluoronitrobenzene is demonstrated with various O/S/N-nucleophiles. Solvent screens substantiate the role of a nonpolar solvent in ortho-selective nucleophilic substitution through a six-membered polar transition state.

NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND

There are provided compounds represented by the following general formula (I) or pharmaceutically acceptable salts of thereof, which have a superior monoacylglycerol acyltransferase 2 inhibitory action: wherein Ring A represents a partially saturated heteroaryl group, an aryl group or a heteroaryl group, RB represents a C4-18 alkyl group, a C3-8 cycloalkyl group, a partially saturated aryl group, an aryl group, or the following formula (II): wherein V represents the formula -CR11R12-, -CO-, -CO-O-, or -CO-NH-, W represents a single bond or a C1-3 alkylene group, and Ring B represents a C3-8 cycloalkyl group, a C3-8 cycloalkenyl group, a partially saturated heteroaryl group, a saturated heterocyclyl group, an aryl group, or a heteroaryl group, Y represents a nitrogen atom or the formula N+(RF), RF represents a C1-4 alkyl group, and m and n, which may be the same or different, each represent an integer of 0 or 1.

NOVEL BENZIMIDAZOLE COMPOUND, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a novel benzimidazole compound, a pharmaceutical composition for preventing or treating an inflammatory disease comprising said compound, a use of a novel benzimidazole compound for the manufacture of a medicament for prev